Patent 7018395 Issued on March 28, 2006. Estimated Expiration Date: March 16, 2024. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
607/88, Light application607/89, Laser application604/21, With tubular injection means inserted into body424/450, Liposomes96/33, Mounted on rotatable shaft (e.g., swinging arm or hammer, etc.)514/410, Polycyclo ring system having the five-membered hetero ring as one of the cyclos362/194, Battery supported separable lamp assembly540/145, Porphyrins (including hydrogenated; e.g., chlorophyll, etc.)604/20, Infrared, visible light, ultraviolet, X-ray or electrical energy applied to body (e.g., iontophoresis, etc.)606/15, With optical fiber606/7, Angioplasty514/23, Carbohydrate (i.e., saccharide radical containing) DOAI514/2, Peptide containing (e.g., protein, peptones, fibrinogen, etc.) DOAI606/16, With optical fiber126/699, Circular lens607/90, Lamp and casing424/1.41, Attached to lymphokine, cytokine, or other secreted growth regulatory factor, differentiation factor, or intercellular mediator specific for a hematopoietic cell (e.g., interferon, interleukin, macrophage factor, colony stimulating factor, erythropoietin); derivative thereof514/63, Silicon containing DOAI435/6, Involving nucleic acid359/599, DIFFUSING OF INCIDENT LIGHT514/185, Polycyclo ring system540/472, Two of the cyclos share at least three ring members or a ring member is shared by three of the cyclos (e.g., bridged, peri-fused, etc., toxiferin)424/59, TOPICAL SUN OR RADIATION SCREENING, OR TANNING PREPARATIONS534/11, Actinide series metal (At. No. 89+)424/9.363, Hetero ring contains at least eight members607/92, Internal application424/423, Surgical implant or material126/698, With concentrating lens546/256, Additional hetero ring containing362/338, Plural elements on a curved surface606/10, Systems424/1.49, Attached to antibody or antibody fragment or immunoglobulin; derivative362/119, Hand tool (e.g., knife, drill)606/194, Inserted in vascular system362/296, Including reflector362/260, Fluorescent type424/490, Coated (e.g., microcapsules)257/99, With housing or contact structure128/899, Devices placed entirely within body and means used therewith (e.g., magnetic implant locator)607/61, Energy source outside generator body359/708, Including a nonspherical surface606/234, Oral pacifier128/898, Methods607/100, Electromagnetic radiation (e.g., infrared)435/7.9, Assay in which an enzyme present is a label514/46, Adenosine or derivative600/407, Detecting nuclear, electromagnetic, or ultrasonic radiation385/31, Input/output coupler607/93, Light pipe applicator424/136.1, Bispecific or bifunctional, or multispecific or multifunctional, antibody or fragment thereof385/142, Of waveguide core428/323, Including a second component containing structurally defined particles600/424, With means for determining position of a device placed within a body705/14, Distribution or redemption of coupon, or incentive or promotion program514/356, C=O in a C(=O)O group (e.g., nicotinic acid, etc.)600/591, Vagina or uterus128/897, MISCELLANEOUS362/329, Enclosure type359/641, COLLIMATING OF LIGHT BEAM372/39, PARTICULAR ACTIVE MEDIA310/171, Induction generators514/224.5, At least three cyclos in the polycyclo ring system424/182.1, Conjugate includes potentiator; or composition comprising conjugate includes potentiator427/2.13, Layer formed contains chemical reagent or chemically reacts with substrate (e.g., cell stain or fix, pH paper, immobilized antigen)606/14, Placed in body250/307, Methods424/1.29, Coated, impregnated, or colloidal particulate (e.g., microcapsule, micro-sphere, micro-aggregate, macro-aggregate)536/23.1, DNA or RNA fragments or modified forms thereof (e.g., genes, etc.)540/474, The hetero ring contains at least three nitrogens607/2, Electrical therapeutic systems600/473, Infrared radiation424/9.6, Diagnostic or test agent produces in vivo fluorescence424/178.1, CONJUGATE OR COMPLEX OF MONOCLONAL OR POLYCLONAL ANTIBODY, IMMUNOGLOBULIN, OR FRAGMENT THEREOF WITH NONIMMUNOGLOBULIN MATERIAL514/408, The five-membered hetero ring consists of one nitrogen and four carbons606/72, Orthopedic fastener530/351, Lymphokines, e.g., interferons, interlukins, etc.424/9.52, Stable gas bubbles containing or intentional solubilized gas containing362/377, Bulb engaging424/1.11, RADIONUCLIDE OR INTENDED RADIONUCLIDE CONTAINING; ADJUVANT OR CARRIER COMPOSITIONS; INTERMEDIATE OR PREPARATORY COMPOSITIONS604/187, Injector or aspirator syringe supported only by person during use (e.g., hand held hypodermic syringe, douche tube with forced injection, etc.)514/177, Oxygen double bonded to a ring carbon of the cyclopentanohydrophenanthrene ring system362/545, Including light emitting diode424/9.362, Porphyrin or derivative thereof315/185R, PLURAL SERIES CONNECTED LOAD DEVICES606/2, Light application604/167.06, Means in conduit to produce fluid tight seal between conduit and element only when element is located within conduit and passing through seal means136/263, Organic active material containing424/130.1, IMMUNOGLOBULIN, ANTISERUM, ANTIBODY, OR ANTIBODY FRAGMENT, EXCEPT CONJUGATE OR COMPLEX OF THE SAME WITH NONIMMUNOGLOBULIN MATERIAL514/9, Cyclopeptides540/140, Heavy metal or aluminum containing514/44Polynucleotide (e.g., RNA, DNA, etc.)
The present invention is drawn to methods for photodynamic therapy (PDT) of a target cell, target tissue or target composition in a mammalian subject, using a therapeutically effective amount of a targeted substance, which is either a targeted photosensitizing agent, or a photosensitizing agent delivery system, or a targeted prodrug. This targeted substance preferably selectively binds to the target cell, target tissue or target composition. Light at a wavelength or waveband corresponding to that which is absorbed by the targeted substance is then administered. The light intensity is relatively low, but a high total fluence is employed to ensure the activation of the targeted photosensitizing agent or targeted prodrug product.
Adilia et al., “Local delivery of photosensitizing drugs in arteries: a novel approach to photodynamic therapy for the prevention of intimal hyperplasia”, Proc. SPIE-INT. Soc. Opt. Eng., 2395:402-8 (1995) (Ger. Symp. Laser Angioplasty, 2nd, 1980).
Anderson et al. “Photodynamic therapy for sarcoma pulmonary metastases: a preclinical toxicity study,” Anticancer Res. 23:3713-3718 (2003).
Anonymous (May 1998) “The 1998 Photonics Circle of Excellence Award Winners”, Photonics Spectra, pp. 95-96.
Barr et al., Normal tissue Damage Following Photodynamic Therapy: Are There Biological Advantages?, Book: Photodynamic Therapy, Basic Principles and Clinical Applications, Barbara W. Henderson and Thomas J. Dougherty, (Eds.); Marcel Dekker, Inc. New York, pp. 201-216.
Bayer et al., “Raw eggs and cancer therapy”, Science Spectra, 12:34-41 (1998).
Beems et al., Photosensitizing properties of bacteriochlorophyllin a and bacteriochlorin a, two derivatives of bacteriochlorophyll a, Photochem. Photobiol. 46(5):639-643 (1987).
Bellnier et al., Murine pharmacokinetics and antitumor efficacy of the photodynamic sensitizer 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a, J. Photochem. Photobiol. B: Biol. 20: 55-61 (1993).
Birchler et al., “Selective Targeting and Photocoagulation of Ocular Angiogenesis Mediated by a Phage-Derived Human Antibody Fragment”, Nature Biotechnol., 17:984-988 (1999).
Blaauwgeers et al., “Polarized Vascular Endothelial Growth Factor Secretion by Human Retinal Pigment Epithelium and Localization of Vascular Endothelial Growth Factor Receptors on the Inner Choriocapillaris”, American Journal of Pathology, 155(2): 421-428 (1999).
Boulton et al., “VEGF localization in diabetic retinopathy”, Br J Opthalmol, 82:561-568 (1998).
Brower, V., “Tumor Angiogenesis—New Drugs on the Block”, Nature Biotechnol., 17:963-968 (1999).
Casalini et al., “Tumor Pretargeting: Role Of Avidin/Streptavidin On Monoclonal Antibody Internalization”, J.Nuclear Med., 38 (9):1378-1381 (1997).
Cattel et al., “The Role of Conjugation Processes and Linking Agents in the Preparation of Molecular/Particulate Conjugates—a Review”, S.T.P. Pharma. Sci., 9 (4):307-319 (1999).
Certified English Translation of Japanese Kokai [Unexamined Patent] No. 57-185220, “Anti-Cancer Drug Having Chlorophyll Derivative Effective,”.
Certified English Translation of Japanese Patent Application No. Sho51-159879 (Japanese Kokai [Unexamined Patent] No. 53-84998), “Carcinostatic Method,”.
Certified English Translation of: Fischer, H. et al., “[On the Bromination of the Esters of Mesoisochlorin e4 and Mesochlorin e6],” Berischte der Deutschen Chemischen 75:1778-1795 (1942).
Chen et al., “New Technology for Deep Light distribution in Tissue for Phototherapy”, The Cancer J., 8 (2):154-163 (2002).
Chen et al., “New directions in photodynamic therapy,” ICCP-2. 2nd International Conference on Porphyrins and Phthalocyanines, Jun. 30 Component, 2002; Kyoto, Japan: 78 [abstract S-26].
Chen, J., “Next Generation Light Delivery System for Multi-Treatment Extended Duration Photodynamic Therapy (MED-PDT)”, SPIE-Proceedings Series, 2972:161-167 (1997).
Ciulla et al., “Changing therapeutic paradigms for exudative age-relted macular degeneration: antiangiogenic agents and photodynamic therapy”, Exp. Opin. Invest. Drugs, 8(12):2173-2182 (1999).
Dartsch, et al., “Photodynamic therapy of vascular stenoses? Response of cultured human smooth muscle cells from non-atherosclerotic arteries and atheromatous plaques following treatment with photosensitizing porphyrins”, Proc. SPIE-INT. Soc. Opt. Eng., 1462:77-80 (1990).
Database Crossfire Beilstein, Database Acession No. 4286587 (Reaction ID), for Levinson, E.G. et al., Russ. J. Bioorg. Chem (Engl. Transl.) 21(3):199-203 (1995) in Russian in the :Bioorg. Khim. 21(3):230-234 (1995).
Derwent English Abstract, Accession No. 1996-475153, citing Russian Patent RU 2054944 C, published Feb. 27, 1996, “Production of purpurin-18 for treatment of tumours—comprises extracting vegetable waste with ethanol, oxidative splitting, degreasing and purifying”.
Dictionary of Cell Biology, Second Edition (Lackie & Dow, eds., 1989), p. 17.
Dillon et al., “In Vitro and In Vivo Protection Against Phototoxic Side Effects of Photodynamic Therapy by Radioprotective Agents WR-2721 and WR-77913”, Photochemistry and Photobiology , 48(2):235-238 (1988).
Dimitroff et al., “Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: Implications for combination treatment with photodynamic therapy”, Investigational New Drugs , 17:121-135 (1999).
Dougherty et al., Review “Photodynamic Therapy”, J. Natl. Cancer Inst. , 90(12):889-905 (1998).
Dougherty, T.J., “A Brief History of Clinical Photodynamic Therapy Development at Roswell Park Cancer Institute”, J. Clin. Laser Med. & Surg ., 14(5):219-221 (1996).
Dougherty, T.J., Photosensitization of malignant tumors, Seminars in Surgical Oncology 2:24-37 (1986).
Edamatsu et al., “One and Two-Photon Selective Excitation Spectroscopy of CuC1 Quantum Dots”, Review , 17:15-16 (1998).
Fact Sheet: Laser Medical Pac, pp. 1-2 (1998).
Ferrario et al., “Antiangiogenic Treatment Enhances Photodynamic Therapy Responsiveness in a Mouse Mammary Carcinoma”, Cancer Research , 60:4066-4069 (2000).
Fischer, H. et al., “[On the Bromination of the Esters of Mesoisochlorin e4 and Mesochlorin e6]3” Berischte der Deutschen Chemischen 75:1778-1795 (1942).
Fisher, W.G. et al. “Simultaneous Two-Photon Activation of Type-1 Photodynamic Therapy Agents,” Photochem. Photobiol., 66(2):141-155 (1997).
Freiherr, G., “Advances in Photodynamic Therapy Lure Device Innovators”, Medical Device & Diagnostic Industry, http://firstname.lastname@example.org, 4 pages.
Gagel, M. P., Photodynamic therapy with porphyrins (1997), available at http://www.dermatology.org/laser/pdt.html.
Gilson et l., “Therapeutic ratio of photodynamic therapy in the treatment of superficial tumours of skin and subcutaneous tissues in man”, J. Cancer, 58:665-667 (1988).
Granville et al., “Photodynamic Treatment with Benzoporphyrin Derivative Monoacid Ring A Produces Protein Tyrosine Phosphorylation Events and DNA Fragmentation in Murine P815 Cells”, Photochem. Photobiol., 67(3):358-362 (1998).
Gryshuk et al., “A First Comparative Study of Purpurinimide-based Fluorinated vs. Nonfluorinated Photosensitizers for Photodynamic Therapy”, Photochem. Photo biol., 76(5):555-559 (2002).
Haas et al., “Phototherapy of Bladder Cancer: Dose/Effect Relationships,” Journal of Urology, 136:525-528 (1986).
Haslam et al., “Recent Developments in Methods for the Esterification and Protection of the Carboxyl Group,” Tetrahedron 36:2409-2433 (1980).
Henderson et al., An in vivo quantitative structure-activity relationship for a congeneric series of pyropheophorbide derivatives as photosensitizers for photodynamic therapy, Cancer Research 57: 4000-4007 (1997).
Jacka et al., “A Lamp for Cancer Phototherapy”, Aust. J. Phys., 36:221-226 (1983).
Jiang et al., “Enhanced photodynamic killing of target cells by either monoclonal antibody or low density lipoprotein mediated delivery systems”, J. Controlled Release , 19:41-58 (1992).
Jiang et al., “Selective Depletion of a Thymocyte Subset in Vitro with an Immunomodulatory Photosensitizer”, Clin. Immunol., 91(2):178-87 (1999).
Jones et al. “Photodynamic therapy for patients with advanced non-small-cell carcinoma of the lung,” Clin Lung Cancer. 3(1):37-41 (2001).
Kashtan et al., “Photodynamic Therapy of Colorectal Cancer Using a New Light Source from In Vitro Studies to a Patient Treatment”, Dis. Colon. Rectum. , 39(4):379-383 (1996).
Kessel et al., Photosensitization with bacteriochlorins, Photochem. Photobiol. 58(2): 200-203 (1993).
Kozyrev et al., Effect of substituents in OsO4 reactions of metallochlorins regioselective synthesis of isobacteriochlorins and bacteriochlorins, Tetrahedron Letters 37(22): 3781-3784 (1996).
Kreimer-Birnbaum, M., “Modified Porphyrins, Chlorins, Phthalocyanines, and Purpurins: Second-Generation Photosensitizers for Photodynamic Therapy”, Seminars in Hematology 26(2): 157-173 (1989).
Latham et al., “Biophotonics Applications of High-Power Semiconductor Diode Laser technology”, available at: http://www.arflhorizons.com/Briefs/0001/DE9903.html pp. 1-3 (1998) accessed on (Feb. 6, 2003).
Li et al., “Application of Ruppert's reagent in preparing novel perfluorinated porphyrins, chlorins and bacteriochlorins”, J. Chem. Soc. Perkin Trans 1, 1785-1787 (1999).
Li et al., “Synthesis, comparative photosensitizing efficacy, human serum albumin (site II) binding ability, and intracellular localization characteristics of novel benzobacteriochlorins derived from vic-dihydroxybacteriochlorins,”. J Med Chem. 46(25):5349-5359 (2003).
Lin et al., “Skin Necrosis due to Photodynamic Action of Benzoporphyrin Depends on Circulating Rather than Tissue Drug Levels: Implications for Control of Photodynamic Therapy”, Photochem. Photobiol., 68(4):575-583 (1998).
Lustig et al., “A multicenter Phase I safety study of intratumoral photoactivation of talaporfin sodium in patients with refractory solid tumors,” Cancer 98(8):1767-71 (2003).
Marcus, S.L., “Photodynamic Therapy of Human Cancer”, Proceedings of the IEEE , 80(6);869-889 (1992).
Margaron et al., “Photodynamic therapy inhibits cell adhesion without altering integrin expression”, Biochimica et Biophysica Acta, 1359:200-210 (1997).
McMillan et al., “Tumor growth inhibition and regression induced by photothermal vascular tergeting and angiogenesis inhibitor retinoic acid”, Cancer Lett., 137:35-44 (1999).
Meerovich et al., “Photosensitizer for PDT based on phosphonate phthalocyanine derivative”, Proc. SPIE-INT. Scc. Opt. Eng., 2924:86-90 (1996).
Merck Manual of Diagnosis and Therapy, 17th edition (Beers & Berkow, eds., 1999), pp. 816-817 and 1654-1657.
Mew et al., “Ability of Specific Monoclonal Antibodies and Conventional Antisera Conjugated to Hematoporphyrin to Label and Kill Selected Cell Lines Subsequent to Light Activation”, Cancer Res., 45:4380-4386 (1985).
Mew et al., “Photoimmunotherapy: Treatment of Animal Tumors with Tumor-Specific Monoclonal Antibody-hematoporphyrin Conjugates”, Journal of Immunology, 130(3):1473-1477 (1983).
Middleton et al., “Synthetic Biodegradable Polymers as Medical Devices”, Medical Plastics & Biomaterials, pp. 30-39 (1998).
Millson et al., “Ex-vivo Treatment of Gastric Helicobacter Infection by Photodynamic Therapy”, J. of Photochemistry and Photobiology B: Biology, 32:59-65 (1996).
Nakatani et al., “Chemistry and biochemistry of Chinese drugs. VII. Cytostatic pheophytins from silkworn excreta, and derived photocytotoxic pheophorbides”, Chem. Pharm. Bull., 29(8):2261-2269 (1981).
Nemoto et al., “Inhibition by a new biophosphonate (YM175) of bone resorption induced by the MBT-2 tumuor of mice”, Brit. J. Cancer, 67(5):893-897 (1993).
North et al., “Viral Inactivation in Blood and Red Cell Concentrates with Benzoporphyrin Derivative”, Blood Cells 18:129-140 (1992).
Pandey et al., “Shedding some light on tumours”, Chem. Indust., 1998:739-743 (1998).
Pandey et al., Comparative in vivo sensitizing efficacy of porphyrin and chlorin dimers joined with ester, ether, carbon-carbon or amide bonds, J. Molecular Recognition 9: 118-122 (1996).
Patent Abstract of Japan citing Japanese Patent Application JP 09124652, published May 13, 1997, “Porphyrin Derivative and Use Thereof”.
Pittau et al., “An Inexpensive Light Source for Oncologic Photodynamic Therapy”, IEEE Eng. Med. Biol., pp. 105-106 (1998).
Prewett et al., “Antivascular Endothelial Growth Factor Receptor (Fetal Liver Kinase 1) Monoclonal Antibody Inhibits Tumor Angiogenesis and Growth of Several Mouse and Human Tumors”, Cancer Research, 59:5209-5218 (1999).
Renno et al., “Photodynamic Therapy Using Lu-Tex Induces Apoptosis In Vitro, and Its Effect is Potentiated by Angiostatin in Retinal Capillary Endothelial Cells”, Investigative Opthalmol. & Visual Sci., 41(12):3963-3971 (2000).
Rimington et al., Preparation and photosensitizing properties of hematoporphyrin ethers, Free Rad. Res. Comms. 7(3-6): 139-142 (1989).
Roy et al., “Ceramic-based nanoparticles entrapping water-soluble photosensitizing anticancer drugs: a novel drug-carrier system for photodynamic therapy,” J Am Chem Soc. 125(26):7860-5 (2003).
Ruebner, A. et al. “Carrier Systems in PDT II: Accumulation Strategies of Biotin-Avidin Coupled Photosensitizers Developed On Cultured Tumor Cells,” SPIE, 2625:328-32 (1996).
Rungta et al., Purpurinimides as photosensitizers: effect of the presence and position of the substituents in the in vivo photodynamic efficacy, Bioorg. Medicinal Chem. Letters 10: 1463-1466 (2000).
Savellano et al., “Pegylated BPD Verteporfin C225 Anti-EGF Receptor Direct Covalent Linkage Photosensitizer Immunoconjugates”, Photochem. Photobiol., 69:38S (1999).
Savitsky, A.P. et al. “Avidin-Biotin System for Targeting Delivery of Photosensitizers and Other Cytotoxic Agents Into Malignant Tissues,” SPIE, 3191: 243-53 (1997).
Schmidt et al., “Size-dependent Two-Photon Excitation pectroscopy of CdSe Nanocrystals”, Physical Review B, 53(19):12629-12632 (1996).
Schmidt-Erfurth et al., “In Vivo Uptake of Liposomal Benzoporphyrin Derivative and Photothrombosis in Experimental Corneal Neovascularization”, Lasers in Surgery and Medicine, 17:178-188 (1995).
Schmidt-Erfurth et al., “Photodynamic Therapy of Experimental Choroidal Melanoma Using Lipoprotein-delivered Benzoporphyrin”, Opthalmol., 101:89-99 (1994).
Schmidt-Erfurth et al., “Photodynamic therapy of subfoveal choroidal neovascularization: clinical and angiographic examples”, Graefe's Arch. Clin. Exp. Opthalmol., 236:365-74 (1998).
Schmidt-Erfurth et al., “Vascular targeting in photodynamic occlusion of subretinal vessels”, Opthalmol. , 101(12):1953-1961 (1994).
Sharman et al., “Novel water-soluble phthalocyanines substituted with phosphonate moieties on the benzo rings”, Tetrahedron Lett., 37(33):5831-5834 (1996).
Sigsestad, C.P. et al. “Chemical Modification of Normal Tissue Damage Induced by Photodynamic Therapy,” Brit. J. Cancer 74(Suppl.37);S89-92 (1996).
Smith et al, “Meso substitution of chlorophyll derivatives: direct route for transformation of bacteriopheophorbides d into bacteriopheophorbides c,” J Am Chem Soc 107:4946-54 (1985).
Smith et al., “Bacteriochlorophylls c from Chloropseudomonas ethylicum. Composition and NMR Studies of the Pheophorbides and Derivatives”, Am. Chem. Soc., 102(7):2437-2448 (1980).
Spikes, J.D., Porphyrins and related compounds as photodynamic sensitizers, Annals of the New York Academy of Sciences 244: 496-508 (1975).
Stedman's Medical Dictionary, 26th Edition, (Williams & Wilkens, 1995), pp. 268, 276-280, 726-727, 1165, 1182, and 1571-1572.
Stemberg et al., “Porphyrin-based Photosensitizers for Use in Photodynamic Therapy”, Tetrahedron, 54:4151-4202 (1998).
Su, F., Photodynamic Therapy: A Maturing Medical Technology, OE-Reports, SPIE, Feb. 2000, available at http://www.spie.org/web/oer/february/feb00/phototherapy.html.
Szeimies et al., “A New Light Source for PDT of Skin Lesions”, http://www.lumacare.com/paper3.htm, 2 pages (after 1993).
Szeimies et al., “A Possible New Incoherent Lamp for Photodynamic Treatment of Superficial Skin Lesions”, Acta Derm Venereol, 74:117-119 (1994).
Taber's Cyclopedic Medical Dictionary, 14th edition (C. L. Thomas, ed., 1983), p. 63.
Tomio et al., “Effect of Hematoporphyrin and Red Light on AH-130 Solid Tumors in Rats”, ACTA Radiologica Oncol., 22:49-53 (1983).
Umemura et al., “Recent Advances in Sonodynamic Approach to Cancer Therapy,” Ultrasonics Sonochemistry, 3:S187-S191 (1996).
Whitehurst et al., “Development of an Alternative Light Source to Lasers for Photodynamic Therapy: 1. Comparative In Vitro dose Response Characteristics”, Lasers in Med. Sci., 8:259-267 (1993).
Wieman et al., “(418) Photodynamic Therapy (PDT) of Locally Recurrent Breast Cancer (LRBC) with Lutetium Texaphyrin (Lutrin)”, American Society of Clinical Oncology, 18:111A (1999).
Wilder-Smith et al., “(G1546) Photoeradication of Helicobacter pylori in Humans: Phase 1 Study”, AGA Abstracts Gastroenterology, 116(4):A354 (1999).
Wood et al., “A beam-splitting device for use with fiber-coupled laser light sources for photodynamic therapy,” Photochem Photobiol. 76(6):683-5 (2002).
Woodburn et al., Evaluation of porphyrin characteristics required for photodynamic therapy, Photochem. Photobiol. 55(5): 697-704 (1992).
Yamamoto et al., “Photodynamic effects on the nucleic acids of cancer cells sensitized by sodium phytochlorin”, Medicine and Biology, 90(6):397-400, English translation and certificate of translation included, 4 pages (Jun. 10, 1975).
Yamamoto et al., “Photoradiation therapy, phytochlorin and visible light”, Prevention and Detection of Cancer, Part 1, Prevention. Volume 2, Etiology-Prevention Methods, Proceedings of the Third International Symposium on Detection and Prevention of Cancer held Apr. 26, 1976 in New York, N.Y., 1(2):1789-1802 (1978).
Yamamoto, T., “Effect of phytochlorin on transplantable cancer cells”, Medicine and Biology, 89(6):433-438, English translation and certificate of translation included, 7 pages (Dec. 10, 1974).
Yamamoto, T., “Suppression of tumors by the photodynamic action of phytochlorin sodium”, Medicine and Biology, 90(4):161-164, English translation and certificate of translation included, 4 pages (Apr. 10, 1975).
Yumita et al., “Sonodynamically Induced Antitumor Effect of Gallium-Porphyrin Complex by focused Ultrasound on Experimental Kidney Tumor”, Cancer Letters, 112:79-86 (1997).
Yumita et al., “The Combination Treatment of Ultrasound and Antitumor Drugs on Yoshida Sarcoma”, Japan J. Hyperthermic Oncol., 3(2):175-182 (1987).
Zheng et al., “Photosensitizers Related to Purpurin-18-N-alkylimides: A Comparative in vivo Tumoricidal Ability of Ester versus Amide Functionalities”, Bioorganic & Med. Chem. Letts., 10:123-127 (2000).
Zheng et al., “Chlorin-based symmetrical and unsymmetrical dimers with amide linkages: effect of the substituents on photodynamic and photophysical properties,” J. Chem. Soc. Perkins 1, pp. 3113-3121 (2000).
Zheng et al., “PDT using a novel LED light source and LS11 in a rat liver model,” 30th Annual Meeting of the American Society for Photobiology; Jul. 13-17, 2002; Quebec City, Canada. American Society for Photobiology: 33 [abstract 95].